Mirati Therapeutics | MRTX - Le Bénéfice D'Exploitation



Le Bénéfice D'Exploitation Changement Date
Agios Pharmaceuticals USD -110.02M 11.55M 2026-03
Alnylam Pharmaceuticals USD 112.6M 24.99M 2026-06
Amgen USD 4.61B 777M 2026-06
Astellas Pharma JPY 185.36B 136.79B 2026-06
AstraZeneca USD 3.16B 3.95B 2026-06
Bayer EUR 827M 2.7B 2026-06
BioCryst Pharmaceuticals USD 98.46M 161.92M 2026-06
Bristol-Myers Squibb USD 299M 3.07B 2026-06
Eisai JPY 24.73B 35.04B 2026-06
Eli Lilly USD 12.46B 2.68B 2026-06
Exelixis USD 248.41M 2.93M 2026-06
Gilead Sciences USD 3.85B 1.17B 2026-06
GlaxoSmithKline GBP 2.6B 312M 2026-06
Incyte USD 700.4M 376.22M 2026-06
Ionis Pharmaceuticals USD -102.29M 15.71M 2026-06
J&J USD 7.48B 860M 2026-06
Merck USD 840M 2.72B 2026-06
Moderna USD -815M 573M 2026-06
Nektar Therapeutics USD -38.26M 19.17M 2026-03
Novartis USD 4.75B 515M 2026-06
Pfizer USD 667M 4.32B 2026-06
Puma Biotechnology USD 22.08M 24.26M 2024-09
Roche Holding CHF 11.46B 1.91B 2026-06
Sarepta Therapeutics USD 13.29M 345.14M 2026-06
Takeda JPY 201.42B 215.04B 2026-06
Ultragenyx Pharmaceutical USD -75M 141M 2026-06